For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
We use cookies to make our site as useful as possible.
If you continue without changing your settings we'll assume you’re happy.
Read about our cookie policy.
All tags custom products and licensing Antibody discovery using next-generation sequencing
Antibody discovery using next-generation sequencing
Next generation sequencing (NGS) yields many more unique clones than traditional hybridoma methods.
- Greater pool of candidates allows for increased success in finding an antibody that meets specifications
- Better support of discovery efforts for functionally relevant monoclonal antibodies (mAbs) (eg diagnostic and therapeutic)
- >5,000 unique antibody sequences support the resulting intellectual property (IP) portfolio for legal protection around target binding
Customization Outputs of NGS-based antibody selection
- Rationally-selected mAbs
- Sequences and plasmids for at least 30–50 sequence-diverse candidates, scalable to the consumer needs
- Paired NGS data library capturing native VH-VL chains
- IP-supportive portfolio of antibody sequences surrounding mAb leads and humanization advantage
- NGS database for further data mining with bioinformatics support
Contact us
If you have any questions about our custom services, please contact us anytime.
Get in touch
Get resources and offers direct to your inbox
Sign up